Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes.

ABSTRACT:

Background

Patients with cancer and acute ischemic stroke (AIS) face high rates of recurrent thromboembolism or death.

Objectives

To examine whether hematologic and embolic biomarkers soon after AIS are associated with subsequent adverse clinical outcomes.

Methods

We prospectively enrolled 50 adults with active solid tumor cancer and AIS at two hospitals from 2016 to 2020. Blood was collected 72-120 h after stroke onset. A 30-min transcranial Doppler (TCD) microemboli detection study was performed. The exposure variables were hematologic markers of coagulation (D-dimer, thrombin-antithrombin), platelet (P-selectin), and endothelial activation (thrombomodulin, soluble intercellular adhesion molecule-1 [sICAM-1], soluble vascular cell adhesion molecule-1 [sVCAM-1]), and

SUBMITTER: Navi BB 

PROVIDER: S-EPMC9378694 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature